DarioHealth Corp. filings document the regulatory record of a Nasdaq-listed digital health company with common stock registered under the Exchange Act. Recent 8-K reports cover material agreements, including equity offering arrangements, securities purchase agreements and amendments to credit facilities, along with related capital-structure disclosures involving common stock, preferred stock and pre-funded warrants.
The company’s filings also record governance and charter matters, including amendments to its certificate of incorporation, preferred stock designation changes, annual meeting voting results and board appointments. These disclosures frame DRIO’s formal reporting around financing activity, security-holder rights, corporate governance and material events tied to its digital therapeutics business.
DarioHealth Corp. (DRIO) appointed John R. Palumbo as Chairman of the Board on November 3, 2026, effective immediately, on the recommendation of its Nominating Committee. Palumbo succeeds Yoav Shaked, who will continue to serve as a member of the Board.
DarioHealth Corp. director John R. Palumbo acquired 62,000 common shares through a restricted share award dated September 24, 2026. His reported post-transaction position was 66,500 shares of common stock held directly. The reported transaction was a grant/award acquisition, not a market purchase.
DarioHealth Corp. director Adam K. Stern received a direct restricted share award of 28,000 common shares on September 24, 2026, bringing his directly held shares to 57,717. The award vests on the last day of the second-year anniversary after the grant date.
Separately, AKS Family Partners L.P. automatically converted 250 Series C preferred shares into 11,760 common shares at $40.40 per share and 100 Series D-2 preferred shares into 8,435 common shares at $16.60 per share on September 18, 2025. Each preferred position fell to zero.
DarioHealth Corp. director Dennis M. McGrath acquired 61,000 shares of Common Stock in a restricted share award on September 24, 2026. His reported direct holdings after the award were 88,737 shares.
DarioHealth Corp. director Yoav Shaked received a 54,000-share restricted share award on September 24, 2026. The award vests in eight equal quarterly installments on the last day of each successive calendar quarter after the grant date, over two years.
On August 12, 2024, his 40 Series B-2 preferred shares automatically converted into 15,431 common shares, subsequently reported as 772 shares following a reverse stock split. Including dividend shares, Shaked beneficially owned 33,582 common shares immediately after the conversion.
DarioHealth Corp. Chief Financial Officer Chen Franco-Yehuda received a restricted share award for 95,000 common shares on September 24, 2026. His reported direct holdings following the award were 125,000 shares. The award vests in eight equal quarterly installments on the last day of each successive calendar quarter after the grant date, over a two-year period.
DarioHealth Corp. director Dennis Matheis acquired 44,000 shares of Common Stock through a restricted share award on September 24, 2026. The award transaction was reported at $0.0000 per share. His direct Common Stock holdings following the transaction were 87,026 shares.
DarioHealth Corp. director Karah Hila received a 28,000-share restricted share award on September 24, 2026. The reported transaction price was $0 per share, and her directly held common-stock position after the award was 58,965 shares. The award vests in eight equal quarterly installments on the last day of each successive calendar quarter after the grant date, over a two-year period.
DarioHealth Corp. Chief Executive Officer Raphael Erez was granted a direct restricted share award of 297,000 common shares on September 24, 2026; no Rule 10b5-1 plan is reported. Separately, 30 Series B-2 Preferred Stock shares automatically converted on August 12, 2024, into 11,574 common shares, with the conversion shares reported as 579 shares following a reverse stock split. Erez beneficially owned 157,432 common shares immediately following the August 12, 2024 conversion.
DarioHealth Corp. (DRIO) Chief Operating Officer Lara Ann Sherman reported direct ownership of 120,000 common shares, including 95,000 restricted shares granted September 24, 2026, which vest on the second anniversary of the grant date. She also reported a stock option covering 15,000 common shares, with a $16 exercise price and a December 23, 2034 expiration date; 8,750 option shares were vested as of September 24, 2026.